BRANFORD, Conn., Aug. 5 /PRNewswire/ -- Marinus Pharmaceuticals, a developer of specialty therapeutics to treat serious neurological, psychiatric and pain disorders, has appointed John Krayacich as president and chief executive officer. Mr. Krayacich will be responsible for leading the company's drug and business development for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a pre-clinical schizophrenia candidate.
Mr. Krayacich brings more than 20 years of experience in pharmaceutical product development with 13 years focused on neuroscience diseases. Most recently, he was with Novartis Pharmaceuticals Corporation where he served as global program head for the antidepressant agomelatine, and vice president and global head of neuroscience project management.
"We are pleased that John is taking the helm at Marinus, particularly at such a crucial stage of development of the company's lead compound, ganaxolone, a new class of epilepsy treatment," said Stephen Bloch, chair of the board of directors and general partner of Canaan Partners. "Marinus has developed an innovative formulation of ganaxolone which we believe sets a foundation for positive clinical outcomes and makes Marinus an exciting investment opportunity."
Prior to Novartis, Mr. Krayacich was vice president of worldwide neurology marketing with Pfizer Pharmaceuticals Group, and Parke-Davis Global Marketing Planning (Atherosclerosis). He was actively involved in the development, strategic marketing planning and/or launch of more than seven neuroscience and cardiovascular compounds including Lipitor(R), Neurontin(R), Lyrica(R), Rebif(R) and the Exelon(R) patch. He has led teams involved in the development and marketing of products for epilepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, depression, anxiety, Multiple Sclerosis and bipolar disorder.
"I am thrilled to join the Marinus team and to shepherd the company's
|SOURCE Marinus Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved